Quantitative assessment of correction between programmed cell death -1 polymorphism rs10204525 and risk of upper gastrointestinal cancer in Chinese population

doi:10.3877/cma.j.issn.1674-0785.2018.05.011

Abstract

Abstract:

Objective

To assess the association between the programmed cell death-1 (PD-1) polymorphism rs10204525 and risk of upper gastrointestinal cancer in the Chinese population.

Methods

We searched PubMed, MEDLINE, and CNKI databases and retrieved studies (2536 cases and 3491 controls) on the association of PD-1 polymorphism rs10204525 and risk of upper gastrointestinal cancer in the Chinese population. Meta-analysis was performed with Stata statistical package 12.0, with 95% confidence intervals and odds ratios calculated.

Results

Meta-analysis of all the included clinical trials showed that there was no significant association between the PD-1 polymorphism rs10204525 and risk of upper gastrointestinal cancer in the Chinese population in all the genetic models [homozygous (GG vs AA: OR=0.81, 95%CI=0.58~1.15, P=0.236); heterozygous (AG vs AA: OR=0.97, 95%CI=0.87~1.08, P=0.523); dominant (AG+ GG vs AA: OR=0.95, 95%CI=0.86~1.05, P=0.333); recessive (GG vs AG+ AA: OR=0.82, 95%CI=0.58~1.16, P=0.263); and allele (T vs C: OR=0.95, 95%CI=0.88~1.03, P=0.211)].

Conclusion

There was no significant association between the PD-1 polymorphism rs10204525 and risk of upper gastrointestinal cancer in the Chinese population.

Key words: Programmed cell death-1, Polymorphism, Upper digestive tract cancer, Risk, Correlation analysis

Yuetao Zhao, Xiaoming Zheng, Zhiyong Yu, Pei Qin, Chunben Xu. Quantitative assessment of correction between programmed cell death -1 polymorphism rs10204525 and risk of upper gastrointestinal cancer in Chinese population[J]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(05): 310-314.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2018.05.011

https://zhlcyszz.cma-cmc.com.cn/EN/Y2018/V12/I05/310

Figures/Tables 5

References 15

1	Chen W, Zheng R, Baade PD, et al. Cancer statistics in china, 2015 [J]. CA Cancer J Clin, 2016, 66(2):115-132.
2	Hütz K, Mejías-Luque R, Farsakova K, et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells [J]. Carcinogenesis, 2014, 35(4):942-950.
3	Hussain S, M Y, Thakur N, et al. Association of cyclin D1 gene polymorphisms with risk of esophageal squamous cell carcinoma in Kashmir Valley: a high risk area [J]. Mol Carcinog, 2011, 50(7):487-498.
4	王瑞，张健慧，李琰, 等. 食管癌贲门癌易感性与细胞周期蛋白D1基因多态性的关联研究[J]. 中华医学杂志, 2003, 83(12):1089-1092.
5	Blank C, BrownⅠ, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8^＋ T cells [J]. Cancer Res, 2004, 64(3):1140-1145.
6	Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection [J]. Nat Immunol, 2007, 8(3):239-245.
7	Ansell SM, Lesokhin AM, BorrelloⅠ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin′s lymphoma [J]. N Engl J Med, 2015, 372(4):311-319.
8	Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway [J]. Trends Mol Med, 2015, 21(1):24-33.
9	Qiu H, Zheng L, Tang W, et al. Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer [J]. Clin Biochem, 2014, 47(7-8):612-617.
10	Tang W, Chen Y, Chen S, et al. Programmed death-1 (PD-1) polymorphism is associated with gastric cardia adenocarcinoma [J]. Int J Clin Exp Med, 2015, 8(5):8086-8093.
11	Zhou RM, Li Y, Wang N, et al. Association of programmed death-1 polymorphisms with the risk and prognosis of esophageal squamous cell carcinoma [J]. Cancer Genet, 2016, 209(9):365-375.
12	Tang W, Chen S, Chen Y, et al. Programmed death-1 polymorphisms is associated with risk of esophagogastric junction adenocarcinoma in the Chinese Han population: A case-control study involving 2,740 subjects [J]. Oncotarget, 2017, 8(24):39198-39208.
13	王月华，胡志远. PD-1/PD-L1在肿瘤免疫逃逸中的作用机制及其临床应用[J]. 中国肿瘤生物治疗杂志, 2017, 24(7):784-790.
14	Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas [J]. Clin Sarcoma Res, 2016, 6:24.
15	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer [J]. N Engl J Med, 2015, 373(17):1627-1639.

研究者	年份	肿瘤类型	人群国籍	例数（病例组/对照组）	匹配标准	对照人群来源	基因分型方法	是否符合HWE
Qiu等^[9]	2014	食管癌	中国	629/686	年龄、性别	医院来源	PCR-LDR	符合
Tang等^[10]	2015	胃贲门腺癌	中国	330/608	年龄、性别	医院来源	PCR-LDR	符合
Zhou等^[11]	2016	食管鳞状细胞癌	中国	584/585	年龄、性别	内镜普查	PCR-LDR	符合
Tang等^[12]	2017	食管胃交界腺癌	中国	1063/1677	年龄、性别	健康体检	SNPscanTM	符合

研究者	年份	肿瘤类型	人群国籍	例数（病例组/对照组）	匹配标准	对照人群来源	基因分型方法	是否符合HWE
Qiu等^[9]	2014	食管癌	中国	629/686	年龄、性别	医院来源	PCR-LDR	符合
Tang等^[10]	2015	胃贲门腺癌	中国	330/608	年龄、性别	医院来源	PCR-LDR	符合
Zhou等^[11]	2016	食管鳞状细胞癌	中国	584/585	年龄、性别	内镜普查	PCR-LDR	符合
Tang等^[12]	2017	食管胃交界腺癌	中国	1063/1677	年龄、性别	健康体检	SNPscanTM	符合

作者	年份	肿瘤类型	病例组基因分布					对照组基因分布					样本量（病例组/对照组）
作者	年份	肿瘤类型	AA	AG	GG	A	G	AA	AG	GG	A	G	样本量（病例组/对照组）
Qiu等^[9]	2014	食管癌	317	240	43	874	326	345	243	63	933	369	600/651
Tang等^[10]	2015	胃贲门腺癌	169	123	21	461	165	309	219	53	837	325	313/581
Zhou等^[11]	2016	食管鳞状细胞癌	325	226	33	876	292	296	238	51	830	340	584/585
Tang等^[12]	2017	食管胃交界腺癌	544	397	98	1485	593	870	672	132	2412	936	1039/1674

作者	年份	肿瘤类型	病例组基因分布					对照组基因分布					样本量（病例组/对照组）
作者	年份	肿瘤类型	AA	AG	GG	A	G	AA	AG	GG	A	G	样本量（病例组/对照组）
Qiu等^[9]	2014	食管癌	317	240	43	874	326	345	243	63	933	369	600/651
Tang等^[10]	2015	胃贲门腺癌	169	123	21	461	165	309	219	53	837	325	313/581
Zhou等^[11]	2016	食管鳞状细胞癌	325	226	33	876	292	296	238	51	830	340	584/585
Tang等^[12]	2017	食管胃交界腺癌	544	397	98	1485	593	870	672	132	2412	936	1039/1674

[1]	Huanyan Liu, Yang Hua, Lingyun Jia, Xinyu Zhao, Beibei Liu. Lumen structure and hemodynamic characteristics of occluded internal carotid artery [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 809-815.
[2]	Yanbo Ma, Yang Hua, Guimei Liu, Xiufeng Meng, Liping Cui. Risk factors for carotid atherosclerotic lesions in middle adults [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 822-826.
[3]	Yingxiong Huang, Zi Ye, Peng Jiang, Hong Zhan, Chen Yao, Ji Cui. Clinical risk factors for transmural intestinal necrosis in acute mesenteric venous thrombosis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 413-421.
[4]	Zaibo Zhang, Bingyu Wang, Zhikai Jiao, Bibo Tan. Risk factors for lower extremity deep venous thrombosis after gastric cancer surgery: A Meta-analysis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 475-480.
[5]	Xuyuan Chen, Shiyun Luo, Wenzhong Li, Yi Li. Analysis of risk factors for wound healing difficulties after operative treatment of adenogenic anal fistula [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 82-85.
[6]	Xu Tang, Bing Han, Wei Liu, Ruxing Chen. Analysis of risk factors for metachronous liver metastases after radical colorectal cancer surgery and construction of a predictive model [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 16-20.
[7]	Fangyuan Wu, Xia Sun, Changfeng Lin, Zhensheng Zhang. Risk factors of HBV-associated cirrhosis complicated with acute upper gastrointestinal bleeding [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 45-47.
[8]	Qingyan Yan, Xiaomei Yong, Hong Luo, Min Du. Prognostic factors and survival analysis of multicenter elderly patients with metastatic breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 636-638.
[9]	Xian Mo, Chuang Yang. Meta-analysis of risk factors for portal vein thrombosis in patients with cirrhosis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 678-683.
[10]	Xiaodan Wang, Yuan Wang, Xiangyu Cui, Xiaolei Ren. Analysis of pathogenic bacteria resistance of drug and high risk factors of death in urogenic sepsis after endoscopic surgery for upper urinary tract stones [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(06): 611-615.
[11]	Yonghuan Mao, Hanwen Tong, Ji Miao, Xingzhou Wang, Xiaofei Shen, Chunzhao Yu. Analysis of risk factors and prediction model of parastomal hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 682-687.
[12]	Wenbin Lin, Zeyuan Zheng, Wenneng Zheng, Yigang Yu. Construction of prediction model for risk of conversion to open surgery in patients with traumatic splenic rupture undergoing laparoscopic splenectomy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 619-623.
[13]	Wenkai Ni, Chong Qi, Xiaodan Xu, Xiecheng Zhou, Qingzhang Yin, Yuankun Cai. Analysis of influencing factors of prolonged postoperative ileus in patients with colorectal cancer after operation [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 484-489.
[14]	Menggui Lu, Bin Huang, Qiulin Li, Yuanmei He. Risk factors for multiple organ dysfunction syndrome in patients with bee sting injury [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 1010-1015.
[15]	Da Li, Daya Zhang, Runxiang Chen, Xiaodong Zhang, Shimei Huang, Chen Chen, fan Zeng, Shiju Chen, Feihu Bai. Epidemiological characteristics and risk factors of Helicobacter pylori infection in Dongfang city of Hainan province [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 858-864.

Please choose a citation manager

Content to export